We’ve assembled a team of scientists, drug hunters, executives, and visionaries. Our experience is matched only by our passion.
Our team includes industry leaders and seasoned executives all drawn to the common purpose of realizing our mission to deliver on the promise of messenger RNA (mRNA) science to bring new medicines to patients. In addition to extensive experience in the biopharma industry, we share a commitment to the possibilities that mRNA science brings to medicine and a desire to rapidly and effectively advance the science to benefit patients.
Moderna Executive Committee
- Stéphane Bancel, Chief Executive Officer
- Joe Bolen, Ph.D., Chief Scientific Officer
- Stephen W. Harbin, Senior Vice President, Human Resources and Clinical Supply Operations
- Stephen Hoge, M.D., President
- James R. Kasinger, General Counsel
- Lorence Kim, M.D., Chief Financial Officer and Senior Vice President, Business Development
- Tal Zaks, M.D., Ph.D., Chief Medical Officer
Stéphane joined Moderna in the summer of 2011 when it was a one employee and one patent company, after Dr. Noubar Afeyan and the board described to him the technology behind messenger RNA Therapeutics™. He has assembled a world-class team and raised the company’s financing.
He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMerieux has more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion. During his five years with bioMérieux, he accelerated the company’s sales growth rate from a historic rate of 4-5% per year to above 9% per year, grew EBIT at 12% CAGR (versus a historical growth rate of 4-5%), enhanced its position as the global leader in clinical microbiology and re-accelerated its immuno-assay franchise by focusing on high medical value biomarkers. He led the company through 10 successful acquisitions in the U.S., Europe, and Asia/Pacific without needing new capital from shareholders. During that time, the company’s market capitalization nearly doubled despite the 2008 financial crisis.
Prior to his time at bioMérieux, Stéphane was managing director of Eli Lilly in Belgium and executive director of global manufacturing strategy and supply chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in their UK manufacturing plant outside London.
He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School.
Stéphane is named as an inventor on over 45 patent filings in the field of messenger RNA technology. These filings include claims covering a broad range of novel compositions and formulations as well as manufacturing and clinical methods in the fields of human and animal therapeutics, diagnostics and cell processing.
Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for investor relations in France in 2009 and was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. Stephane serves as a supervisory director of Qiagen N.V., executive chairman of the board of BG Medicine, Inc., and on the Board of Directors of Syros Pharmaceuticals.
As chief scientific officer, Dr. Joseph Bolen oversees scientific technology development and drug discovery research at Moderna and its ventures. Prior to joining Moderna, Dr. Bolen was the chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company, where he held various senior positions beginning in 1999. He has also held leadership positions at Hoechst Marion Roussel and the Bristol-Myers Squibb Pharmaceutical Research Institute, and was the founding director of the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California.
Dr. Bolen brings a proven track record of leading a large and multi-faceted international R&D organization while fostering a culture of scientific innovation within a global commercial-stage company. He has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research since starting his career as a scientist at the National Institutes of Health (NIH).
Dr. Bolen has published more than 200 peer-reviewed scientific articles and book chapters, and has presented hundreds of lectures and seminars at leading universities, as well as at national and international scientific meetings. He has served on numerous journal editorial boards as well as study sections, panels and committees for the National Institutes of Health, the National Aeronautics and Space Administration, the Howard Hughes Medical Institute, the American Cancer Society, the American Association for Cancer Research and academic institution scientific advisory boards.
Dr. Bolen graduated from the University of Nebraska with a B.S. in microbiology and chemistry and a Ph.D. in immunology. He pursued postdoctoral training in molecular virology at the Kansas State University Cancer Center where his research was directed towards analysis of the polyoma DNA tumor virus.
Steve brings more than 30 years of diverse operational experience in pharmaceuticals and in-vitro diagnostics to his position at Moderna, having served in a variety of senior business and operational leadership roles both in Europe and the U.S. Prior to joining Moderna, he was the corporate vice president of Global Operations at bioMérieux, where he was responsible for more than 3,000 global employees over multiple global functions and manufacturing sites.
In his career Steve has held senior leadership positions driving strategic direction and performance in such areas as, manufacturing, information systems, quality, regulatory affairs, and compliance. He has continually refined and reengineered internal processes driving transformation in response to new business challenges.
Steve has held leadership roles with Eli Lilly and Company, Shionogi Qualicaps (Spain), Elanco Qualicaps (U.K.), and Elanco Animal Health where his work covered many different dimensions from sales and marketing to HR and people development in highly regulated environments, resulting in receiving ‘best practice’ recognition from the FDA.
He graduated in 1979 from Durham College of Agriculture in the UK.
As President of Moderna, Inc., Stephen is responsible for Moderna’s efforts to develop the most advanced mRNA technology platform across research areas, production and process development. He is the inventor of multiple mRNA patents. Prior to Moderna, Stephen was a partner at McKinsey & Company and a leader in the firm’s healthcare and corporate finance practices. At McKinsey Stephen advised senior management teams of leading biotech and pharmaceutical companies on a wide range of strategic, financial and operational issues. Currently, Stephen serves on the board of directors of Pronutria Inc.
Prior to joining the firm, Stephen was a physician in New York. He holds an M.D. with thesis from the University of California, San Francisco and a B.S. in neuroscience from Amherst College.
Jim leads all legal, corporate governance, and intellectual property matters at Moderna.
A highly accomplished attorney with more than 16 years of experience, Jim brings to Moderna an extensive background in corporate law, mergers and acquisitions, securities, and licensing law. Before joining Moderna, Jim was the general counsel at PlumChoice, Inc., a provider of technical support services to Fortune 1000 companies. Prior to PlumChoice, Jim was a partner at the global law firm, Goodwin Procter LLP, where he represented life sciences, technology and other high-growth companies in all stages of their life cycles, from formation, to obtaining seed and growth financings, to initial public offering, merger or sale. Jim started his legal career at Testa, Hurwitz & Thibeault.
Jim holds a JD from Boston College Law School, graduating cum laude, and a B.A. from Wheaton College, graduating magna cum laude.
Lorence joins Moderna from Goldman Sachs where he was a managing director and co-head of the U.S. biotechnology investment banking effort. He joined Goldman Sachs in 1999 as a summer associate and was named managing director in 2008. As a member of the healthcare investment banking group for nearly 14 years, Lorence’s responsibilities included corporate finance and mergers and acquisitions (M&A) for the pharmaceutical and biotechnology industries, with several billion in equity and equity-linked financings, and more than $55 billion in M&A transactions. Lorence is currently a member of the board of directors of Seres Health.
Prior to joining Goldman Sachs, Lorence worked in various medical research and consulting positions concurrent with his graduate studies. Lorence graduated from Harvard University, magna cum laude and Phi Beta Kappa with an A.B. in biochemical sciences in 1995. He also earned an MBA in healthcare management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000 and an M.D. from the University of Pennsylvania’s School of Medicine in 2000.
As chief medical officer, Dr. Tal Zaks oversees preclinical development, clinical development and regulatory affairs across Moderna and its ventures. Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all aspects of oncology drug discovery, development and commercialization.
Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr. Zaks is associate professor of medicine at the University of Pennsylvania, and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers.
Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.
Stephen has extensive pharmaceutical industry experience in oncology. After 16 years as an academic clinician, he started his industry career at Sugen, and later was vice president of hematology/oncology at Genentech. While at Genentech, Stephen played a significant role in the development of key products Perjeta®, Kadcyla® and Erivedge®, as well as other molecules in the company’s oncology portfolio. He left Genentech in 2009 to run Geron’s oncology division, where he served for four years as executive vice president, research and development, and chief medical officer helping to develop therapeutics and vaccines to fight cancer.
Most recently Stephen was senior vice president, new projects at the cancer therapies company Medivation. Stephen graduated with a Doctorate of Medicine (M.D.) from the University of Birmingham, UK and is a fellow of both the Royal Colleges of Physicians and Pathologists, UK.